Source link : https://www.newshealth.biz/health-news/response-duration-after-stopping-enfortumab-vedotin-in-bladder-cancer/
Patients with metastatic urothelial carcinoma who achieved a complete response after more than 8.5 months of single-agent enfortumab vedotin (Padcev) were able to be off treatment for over 2 years before needing to restart therapy, according to retrospective data presented at the recent European Society for Medical Oncology annual congress in Barcelona. In this exclusive […]
Author : News Health
Publish date : 2024-11-15 19:46:06
Copyright for syndicated content belongs to the linked Source.
inHealth